COVID-19

Top news of the week from Pharmacy Times®.

An increasing amount of evidence points to the possibility of COVID-19 causing cardiovascular-neurological dysfunction.

Long-term care (LTC) pharmacies caring for this population face a myriad of unique obstacles, especially the regulatory framework surrounding them.

Angiotensin peptides are short proteins that regulate the cardiovascular system and are altered in patients with heart failure and those with COVID-19, according to the press release.

Favipiravir is not approved by the FDA. It is being researched in the United States as a potential treatment of COVID-19.

Prepping for flu season in 2020: why the vaccine is more important than ever.

Data show that immunotherapy doesn’t necessarily worsen complications for patients with both COVID-19 and cancer.

As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.

The review also summarized proposed mechanisms behind these wide-ranging systemic effects and provided clinical guidance for physicians, according to a press release.

The test is intended to determine whether someone is currently infected with COVID-19 and if they have been infected in the past.

Without an FDA approved treatment or vaccine for COVID-19, masks are the best form of protection, according to the CDC.

Steven C. Anderson, FASAE, CAE, IOM, president and CEO of the National Association of Chain Drug Stores, has been invited to join the office of Health and Human Services’ new COVID-19 Vaccine Consultation Panel.

As increasing numbers of COVID-19 patients require intubation, aerosol containment devices have been in high demand, including improvised protection strategies and devices.

Phase 1/2 trials show promising results as the study moves into phase 2/3.

Along with the duty to care for patients with COVID-19 is the psychological burden that develops in frontline care professionals, such as pharmacists.

Contrary to earlier data, a new study from the University of California at San Francisco (UCSF) suggests that younger age may not reduce the severity of coronavirus disease 2019 (COVID-19).

Results of the COVID-19 and Cancer Consortium cohort study were presented during the 2020 American Society of Clinical Virtual Scientific Program.

Cancer medications contribute substantially to the cost of health care in the United States, with 8 of the 10 most expensive drugs indicated for the treatment of cancer

The goal of the current format for retail pharmacy services is to continue providing people with the medications they need to maintain their health and longevity during the coronavirus disease 2019 pandemic.

As a chronic respiratory disease, asthma has been considered a risk factor for COVID-19 by many experts and clinicians.

Top news of the week from Pharmacy Times®.

Walgreens and DoorDash plan to offer more than 5000 items for delivery on the DoorDash platform and will expand the service to other major markets, starting with Cincinnati, Cleveland, Minneapolis, Oklahoma City, Phoenix, Sacramento, and Seattle by the end of summer 2020.

The findings indicate that front-line health care workers are at high risk for COVID-19 and that many health care workers with the virus may not have typical symptoms of a respiratory infection, according to the study authors.

Each patient represents a unique set of challenges that requires focus and knowledge.

The current pandemic has been trauma-inducing for many and telehealth needs to rise to the occasion.

Researchers conducted an online study with 371 participants who viewed a COVID-19 screening session between a hotline agent, chatbot or human, and a user with mild or severe symptoms, according to a press release.

If successful in clinical trials and pending regulatory approval, Pfizer Inc and BioNTech expect to manufacture up to 100 million doses of a COVID-19 vaccine by the end of 2020.

It is likely that in the coronavirus disease 2019 era and its aftermath, we may see worsening adherence to therapy due to known factors that affect adherence and others that are unique to what is happening currently.

Emerging evidence is showing that COVID-19 symptoms may still persist even after recovery.

Pharmacists need new tools to reduce administrative burden and provide the best care to patients.